| __timestamp | Bio-Techne Corporation | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 30945000 | 104381000 |
| Thursday, January 1, 2015 | 40853000 | 100171000 |
| Friday, January 1, 2016 | 45187000 | 102726000 |
| Sunday, January 1, 2017 | 53514000 | 96171000 |
| Monday, January 1, 2018 | 55329000 | 66449000 |
| Tuesday, January 1, 2019 | 62413000 | 42672000 |
| Wednesday, January 1, 2020 | 65192000 | 42534000 |
| Friday, January 1, 2021 | 70603000 | 53311000 |
| Saturday, January 1, 2022 | 87140000 | 82258000 |
| Sunday, January 1, 2023 | 92493000 | 118011000 |
| Monday, January 1, 2024 | 96664000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Bio-Techne Corporation and Celldex Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Bio-Techne's R&D expenses surged by approximately 212%, reflecting a robust commitment to innovation. In contrast, Celldex's R&D spending exhibited volatility, peaking in 2023 with a 180% increase from its 2019 low.
Bio-Techne's consistent growth in R&D investment underscores its strategic focus on long-term innovation, while Celldex's fluctuating expenses highlight the challenges and opportunities in the biotech sector. Notably, the data for 2024 is incomplete, suggesting potential shifts in future trends. As the biotech landscape continues to evolve, these companies' R&D strategies will play a pivotal role in shaping their competitive edge.
Analyzing R&D Budgets: Merck & Co., Inc. vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Novartis AG and Bio-Techne Corporation
Research and Development Investment: Amgen Inc. vs Celldex Therapeutics, Inc.
Zoetis Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
argenx SE or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Viatris Inc. and Celldex Therapeutics, Inc.
R&D Insights: How Bio-Techne Corporation and Lantheus Holdings, Inc. Allocate Funds
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG
Research and Development Expenses Breakdown: Bio-Techne Corporation vs Perrigo Company plc
Research and Development Expenses Breakdown: HUTCHMED (China) Limited vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.